Owner
U
UntitledVerification
Tags
🧠 VIRCHOW TRIAD — COMPLETE HIGH-YIELD MASTER TABLE
I. Overview: Virchow Triad
Component | Core Mechanism | Key Effect on Thrombosis | Exam Anchor |
Endothelial injury / dysfunction | Loss of antithrombotic surface | Platelet adhesion + thrombin generation | Most important for arterial thrombosis |
Abnormal blood flow | Stasis / turbulence | Endothelial activation + factor accumulation | Stasis → veins, turbulence → arteries |
Hypercoagulability | ↑ Procoagulant tendency | Mainly venous thrombosis | Inherited or acquired |
II. Endothelial Injury & Dysfunction
A. Structural Injury (Classic Endothelial Damage)
Feature | Detail | Result |
vWF exposure | Platelet adhesion to subendothelium | Platelet-rich thrombus |
Tissue factor exposure | Activates extrinsic pathway | Thrombin burst |
Flow context | High-flow arteries normally resistant | Injury required for clot |
Exam lock:
Arterial thrombi = platelet-rich (“white thrombi”) → aspirin effective
B. Endothelial Activation (No Gross Injury)
Trigger | Effect |
Turbulence / hypertension | Prothrombotic phenotype |
Hypercholesterolemia | Endothelial activation |
Homocystinemia | Toxic to endothelium |
Cigarette smoke | Oxidative endothelial damage |
Diabetes / metabolic syndrome | ↓ antithrombotic mediators |
Inflammation / infection | ↑ TF, vWF |
C. Prothrombotic Changes in Activated Endothelium
1. Procoagulant Shift
Change | Normal Function | Effect When Reduced |
↓ Thrombomodulin | Activates Protein C | Thrombin stays active |
↓ Protein C | normally Inactivates Va, VIIIa | ↑ Coagulation |
↓ TFPI | Inhibits VIIa-TF | Unchecked extrinsic pathway |
↑ Thrombin | Central amplifier | Platelet activation + inflammation (PAR) |
2. Antifibrinolytic Shift
Change | Effect |
↑ PAI-1 | Blocks t-PA |
↓ t-PA | ↓ Plasmin |
Net result | Clot persists (impaired breakdown) |
III. Abnormal Blood Flow — Stasis & Turbulence
A. Why Normal Laminar Flow Protects
Feature | Protective Effect |
Platelets in central stream | Avoid endothelium |
Fast plasma near wall | Prevents adhesion |
Result | No clot formation |
B. Mechanisms by Which Abnormal Flow Causes Thrombosis
Mechanism | Effect |
Endothelial activation | ↑ TF, ↑ vWF, ↑ PAI-1 |
↑ Platelet contact | Adhesion + aggregation |
Failure to wash out factors | Local coagulation factor buildup |
Failure to deliver inhibitors | ↓ Antithrombin, Protein C/S |
C. Clinical Settings (Flow-Driven Thrombosis)
Condition | Dominant Flow Problem | Thrombus Type |
Atherosclerotic plaque | Turbulence + TF exposure | Arterial |
Aneurysm | Stasis pockets | Mural thrombus |
Post-MI ventricle | Akinetic wall → stasis | Ventricular mural |
Mitral stenosis + AF | LA enlargement + stasis | LA thrombus → stroke |
Polycythemia vera | Hyperviscosity → stasis | Venous |
Sickle cell disease | Microvascular stasis | Microthrombi |
Immobilization | Venous stasis | DVT |
Mnemonic: FAST-T
Fibrillation, Aneurysm, Stasis, Turbulence → Thrombosis
IV. Hypercoagulability (Thrombophilia)
A. Primary (Inherited)
Disorder | Mechanism | Risk |
Factor V Leiden (most common) | Resistance to Protein C | Hetero 5×, Homo 50× |
Prothrombin G20210A | ↑ Prothrombin synthesis | ~3× |
Hyperhomocysteinemia | Protein modification + endothelial injury | Arterial + venous |
Antithrombin III deficiency | Loss of thrombin inhibition | Recurrent VTE |
Protein C deficiency | Failure to inactivate Va, VIIIa | Early VTE |
Protein S deficiency | Cofactor loss for Protein C | Early VTE |
Exam rule:
Young (<50) + recurrent venous thrombosis → think inherited
B. Secondary (Acquired)
Cause | Mechanism |
Pregnancy / OCPs | ↑ Coag factors, ↓ AT-III |
Malignancy (Trousseau) | Tumor procoagulants (mucin) |
Age | ↑ Platelet activation, ↓ PGI₂ |
Smoking | Procoagulant shift |
Obesity | Prothrombotic milieu |
Stasis (HF, trauma) | Factor accumulation |
V. Special Acquired Syndromes
A. Heparin-Induced Thrombocytopenia (HIT)
Feature | Detail |
Drug | Unfractionated heparin (↑ risk vs LMWH) |
Mechanism | Anti-PF4–heparin antibodies |
Paradox | Thrombosis + thrombocytopenia |
Pathology | Platelet activation + endothelial injury |
B. Anti-Phospholipid Antibody Syndrome (APS)
Aspect | Detail |
Thrombosis | Arterial + venous |
Pregnancy loss | Trophoblast injury → placentation failure |
Labs | Prolonged clotting tests (lupus anticoagulant) |
False positives | VDRL (cardiolipin) |
Targets | β₂-glycoprotein I, prothrombin |
Forms | Primary or secondary (e.g. SLE) |
Note | Antibodies alone ≠ disease (5–15% healthy) |
🧠 THROMBOSIS — COMPLETE HIGH-YIELD MASTER TABLE (EXAM-READY)
Domain | Sub-category | Key Features / Details (NO OMISSION) |
General Features of Thrombi | Location | Can form anywhere in the cardiovascular system |
Site dependence | Arterial / Cardiac → endothelial injury or turbulence Venous → stasis | |
Attachment | Focally attached to vessel wall or endocardium | |
Direction of growth | Always towards the hear,Arterial → retrograde (against flow) Venous → toward the heart (with flow) | |
Embolic risk | Propagating tail is poorly attached → fragments → embolus | |
Lines of Zahn | Definition | Laminations in thrombus formed in flowing blood |
Composition | Pale bands → platelets + fibrin Dark bands → RBC-rich layers | |
Significance | Confirms antemortem thrombus | |
Postmortem Clots | Nature | Soft, gelatinous, due to blood settling |
Appearance | Dark red dependent layer + yellow “chicken fat” layer | |
Attachment | Not attached to vessel wall | |
Contrast with thrombi | Thrombi are firm, wall-attached, with gray fibrin strands | |
Mural Thrombi | Definition | Thrombi in heart chambers or aortic lumen |
Cardiac causes | Abnormal contraction (MI, arrhythmias, dilated cardiomyopathy) Endomyocardial injury (myocarditis, catheters) | |
Aortic causes | Ulcerated atherosclerotic plaques Aneurysmal dilation | |
Arterial Thrombi | Occlusion | Frequently occlusive |
Composition | Platelet-rich → “white thrombi” | |
Mechanism | Endothelial injury (ruptured atherosclerotic plaque) Vasculitis, trauma | |
Association | Usually superimposed on atherosclerotic plaque | |
Venous Thrombi (Phlebothrombosis) | Occlusion | Almost invariably occlusive |
Shape | Long cast of the vein, extending toward the heart | |
Composition | RBC-rich fibrin mesh → “red” / “stasis” thrombi | |
Common sites | Lower limb veins (~90%) | |
Other sites | Upper limb veins, periprostatic plexus, ovarian & periuterine veins | |
Special sites | Dural sinuses, portal vein, hepatic vein | |
Valve Thrombi (Vegetations) | Definition | Thrombotic masses on heart valves |
Infective Endocarditis | Cause | Blood-borne bacteria or fungi |
Features | Large, friable vegetations Loaded with organisms | |
Risk | High embolic and destructive potential | |
NBTE | Nature | Sterile vegetations |
Setting | Hypercoagulable states (advanced cancer) | |
Features | Small, bland thrombi along valve closure lines | |
Libman–Sacks Endocarditis | Setting | SLE |
Features | Sterile, verrucous vegetations | |
Distribution | Both sides of valve ± chordae | |
Fates of Thrombus | Main outcomes | Propagation, embolization, dissolution, organization/recanalization |
Propagation | Mechanism | Continued platelet + fibrin deposition |
Effect | ↑ occlusion risk, ↑ embolization risk | |
Embolization | Definition | Thrombus fragment dislodges → embolus |
Determinants | Origin, size, destination | |
Dissolution (Fibrinolysis) | Mechanism | Plasmin-mediated fibrin breakdown |
New thrombi | Loosely cross-linked → lysed easily | |
Old thrombi | Dense polymerized fibrin → lysis resistant | |
Clinical point | t-PA effective only early (hours) | |
Organization | Cellular response | Endothelial cells, smooth muscle cells, fibroblasts grow in |
Outcome | Granulation tissue → fibrous tissue | |
Recanalization | Process | New capillary channels form |
Effect | Partial restoration of blood flow | |
Mycotic Aneurysm | Mechanism | Enzymatic digestion + bacterial seeding |
Result | Vessel wall weakening → infective aneurysm | |
Clinical Importance | Venous thrombi | → Pulmonary embolism (most dangerous) |
Arterial thrombi | → Infarction (heart, brain) | |
Superficial Venous Thrombi | Site | Saphenous veins, varicosities |
Features | Pain, tenderness, swelling, congestion | |
Complications | Skin infection, varicose ulcers | |
Embolization | Rare | |
Deep Venous Thrombosis (DVT) | Sites | Popliteal, femoral, iliac veins |
Risk | High PE risk | |
Symptoms | Pain, edema OR asymptomatic (50%) | |
Detection | Often discovered after PE | |
DVT Risk Factors | Stasis | Bed rest, long travel, HF, immobilization |
Endothelial injury | Trauma, surgery, burns | |
Hypercoagulability | Pregnancy, postpartum, cancer, age >50 | |
Trousseau Syndrome | Definition | Migratory thrombophlebitis |
Association | Pancreatic & other cancers | |
Mechanism | Tumor-secreted procoagulants | |
Arterial Thrombosis | Cause | Atherosclerosis |
Effect | MI, stroke | |
Cardiac Mural Thrombi | Causes | MI, atrial fibrillation, mitral stenosis, myocarditis |
Embolic Targets | From left heart/aorta | Brain, kidneys, spleen |
Reason | High blood flow → infarction prone |
🔑 Ultra-Short Exam Lock
Venous thrombi embolize → lungs; arterial & left-heart thrombi occlude → infarction (heart, brain, kidney, spleen).
DIC
DOMAIN | SUBDOMAIN | DETAILS (ZERO OMISSION) |
Core Definition | Fundamental process | Systemic activation of coagulation leading to widespread fibrin microthrombi in the microcirculation |
Dual pathology | 1️⃣ Thrombosis → tissue hypoxia, microinfarcts, organ dysfunction 2️⃣ Bleeding → consumption of platelets & clotting factors + fibrinolysis | |
Terminology | Called consumptive coagulopathy because platelets & coagulation factors are used up | |
Clinical importance | Causes more bleeding than all congenital coagulation disorders combined | |
Pathogenesis – Initiation | Major trigger 1 | Release of tissue factor / thromboplastic substances |
Sources of tissue factor | • Placenta (obstetric complications) • Amniotic fluid • Cancer cells (especially APL, adenocarcinomas) • Monocytes stimulated by endotoxin/exotoxin in sepsis | |
Major trigger 2 | Widespread endothelial injury | |
Causes of endothelial injury | • Immune complex deposition (SLE) • Temperature extremes (burns, heat stroke) • Severe infections (meningococci, rickettsiae) • SIRS in sepsis or major systemic insults | |
Inflammatory Mediators | Cytokines involved | IL-1 and TNF |
Cytokine effects (endothelium) | ↑ Tissue factor expression ↓ Thrombomodulin | |
Anticoagulant failure | ↓ Thrombomodulin → ↓ Protein C activation →no inactivation of Factor Va, Factor VIIIa | |
Net Hemostatic Shift | Coagulation balance | Procoagulant state dominates |
Final molecular effect | ↑ Thrombin generation + ↓ normal anticoagulant pathways | |
Thrombotic Component | Site of thrombosis | Small vessels — arterioles & capillaries |
Structural change | Widespread fibrin deposition within microvasculature | |
Tissue effects | Microvascular occlusion → ischemia → microinfarcts | |
Hematologic effect | RBCs damaged in narrowed fibrin-lined vessels | |
Resulting anemia | Microangiopathic hemolytic anemia | |
Bleeding Component | Primary cause | Consumption of platelets + clotting factors |
Platelet effect | Thrombocytopenia | |
Coagulation factors | ↓ Levels of clotting factors | |
Secondary Fibrinolysis | Activation | Fibrinolysis secondarily activated |
Key enzyme | Plasmin | |
Plasmin actions | • Cleaves fibrin → FDPs • Cleaves Factor V • Cleaves Factor VIII | |
Fibrin Degradation Products (FDPs) | Platelet effects | Inhibit platelet aggregation |
Coagulation effects | • Antithrombin effects • Impair fibrin polymerization | |
Final Hemostatic Outcome | Overall result | Simultaneous thrombosis + bleeding |
End result | Hemostatic failure | |
Major Clinical Settings | Infective | Sepsis (gram-positive & gram-negative) |
Obstetric | • Placental abruption • Retained dead fetus • Amniotic fluid embolism | |
Malignancy | • Acute promyelocytic leukemia • Adenocarcinomas (tissue factor, mucin) | |
Trauma | Major trauma, especially brain trauma | |
Trauma mechanism | Fat + phospholipids → activate intrinsic pathway | |
Clinical Forms | Acute DIC | • Common in obstetrics & major trauma • Bleeding predominates |
Acute manifestations | • Postpartum hemorrhage • Petechiae, ecchymoses • GI / urinary tract bleeding • Shock • Acute renal failure • Dyspnea, cyanosis • Convulsions, coma (severe) | |
Chronic DIC | • Common in malignancy • Thrombosis predominates | |
Chronic detection | May be incidentally detected via abnormal labs | |
Laboratory Findings | Platelets | Thrombocytopenia |
Coagulation times | Prolonged PT and PTT | |
Fibrinogen | Decreased fibrinogen (often) | |
Fibrinolysis markers | Increased FDPs and D-dimers, PAI 1 increase | |
Prognosis | Determinants | Depends on underlying cause + severity of coagulation/fibrinolysis |
Acute DIC | May be rapidly fatal if not controlled | |
Management | Core principle | Always treat the underlying cause |
Examples | Sepsis, retained placenta, malignancy, trauma | |
Supportive therapy | • Fresh frozen plasma (replace factors) • Platelets if needed | |
Anticoagulation | Heparin may be used cautiously in acute DIC with predominant thrombosis | |
Morphology – General | Distribution | Microthrombi in any organ, especially kidneys, adrenals, brain, heart |
Kidneys | Primary lesions | • Fibrin thrombi in glomeruli |
Associated changes | • Endothelial swelling • Focal glomerulitis • Small cortical infarcts | |
Severe outcome | Bilateral renal cortical necrosis | |
Adrenals | Syndrome | Waterhouse–Friderichsen syndrome |
Pathology | Massive adrenal hemorrhage + necrosis | |
Association | Severe meningococcal sepsis | |
Brain | Lesions | Microinfarcts ± hemorrhage |
Clinical effect | Bizarre or multifocal neurologic signs | |
Anterior Pituitary | Complication | DIC may contribute to Sheehan postpartum pituitary necrosis |
Skin & Mucosa | Lesions | Petechiae and ecchymoses |
Sites | • Skin • Serosal surfaces (pleura, pericardium, peritoneum) • Lungs • Urinary tract mucosa |